# Confirmatory Study of DSP-5423P in Patients With Schizophrenia

> **NCT02287584** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 580 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** DSP-5423P Placebo
- **DRUG:** DSP-5423P 40mg
- **DRUG:** DSP-5423P 80mg
- **DRUG:** DSP-5423P Placebo-to-Flex
- **DRUG:** DSP-5423P Active-to-Flex

## Key facts

- **NCT ID:** NCT02287584
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287584, "Confirmatory Study of DSP-5423P in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02287584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*